Calistoga appoints new chief business officer
This article was originally published in Scrip
Executive Summary
Calistoga Pharmaceuticals, a US company focused on the development of isoform-selective PI3 kinase inhibitors for the treatment of cancer and inflammatory diseases, has named Clifford Stocks chief business officer. He has more than 20 years' experience in the biotech industry, including 15 years at Icos, where he served as an executive officer and vice-president of business development.